GALE has taken a beating lately, down 21% today!
It was recently promoted very heavily and we believe this is the aftermath.
At the same time the promo group was hired, it seems a lot of management at GALE was selling heavily. This might make you want to take caution, and take the time to read the full report we will send you if you sign up to our newsletter!
The report will include in depth information on GALE, short, medium, and long target prices, and much more!
We believe in certain pharmaceutical companies very strongly, but when a heavy promotion is taking place even the best of the best could get hammered!
Check out the recent chart on GALE:
You can see the HUGE dip on heavy volume in February, no good.
About GALE: Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing oncology treatments to address major unmet medical needs to advance cancer care. It is developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide. The companys lead product candidate includes NeuVax (nelipepimut-S or E75), which is in Phase 3 clinical trials for preventing the recurrence of breast cancer. It also develops Folate Binding Protein-E39, a targeted vaccine that is in Phase 1/2 clinical trials for the prevention of recurrence in gynecological cancers, such as ovarian and endometrial adenocarconimas. Galena Biopharma, Inc. has a strategic partnership with Dr. Reddy’s Laboratories Ltd. for the development and commercialization of NeuVax in India. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Lake Oswego, Oregon.
If you would like to know more about GALE, sign up to our FREE newsletter!